A dual PPARα/δ agonist called GFT505 has been indicated to promote markers of liver dysfunction, reduce hepatic lipid accumulation, and decrease hepatic inflammatory gene expression in liver in numerous animal models of NAFLD [60]. This evidence concerns the gene PPARA and metabolic dysfunction-associated steatotic liver disease.